文献速递肝病

肝移植等待名单登记中非酒精性脂肪性肝炎肝硬化的自然史

Natural history of NASH cirrhosis in liver transplant waitlist registrants.
PubMed 文献 · J Hepatol · 2023-06-10

本研究利用美国移植受者科学登记数据库,纳入2016年1月1日至2021年12月31日登记的肝移植等待名单患者,比较非酒精性脂肪性肝炎肝硬化(NASH,n=8,120)与非NASH肝硬化(n=21,409)的移植概率和等待名单死亡率。NASH肝硬化患者移植概率更低、等待名单死亡率更高,且血清肌酐是NASH肝硬化患者MELD评分升高导致移植的关键因素。

要点

  • NASH肝硬化患者90天和1年移植概率显著低于非NASH肝硬化(HR 0.873和0.867)。
  • NASH肝硬化患者90天和1年等待名单死亡率显著高于非NASH肝硬化(HR 1.15和1.25)。
  • NASH肝硬化患者血清肌酐是MELD评分升高导致移植的主要因素。

核心结论

  • NASH肝硬化等待名单登记患者相比非NASH肝硬化患者移植概率更低,等待名单死亡率更高。
  • 血清肌酐是NASH肝硬化患者MELD评分升高导致移植的主要贡献因素。

研究设计与样本

  • 研究队列为2016年1月1日至2021年12月31日期间登记在肝移植等待名单的患者,使用移植受者科学登记数据库。
  • 比较NASH肝硬化(n=8,120)与非NASH肝硬化(n=21,409)患者,主要结局为移植概率和等待名单死亡率。

主要发现

  • NASH肝硬化患者登记时MELD评分较低,但门静脉高压负担更重,尤其在低MELD评分时。
  • NASH肝硬化患者90天移植概率显著低于非NASH肝硬化(HR 0.873,p<0.001),1年移植概率亦显著低于非NASH肝硬化(HR 0.867,p<0.001)。
  • MELD评分>30的患者中,NASH肝硬化患者90天移植概率(HR 0.705)和1年移植概率(HR 0.672)均显著低于非NASH肝硬化(p均<0.001)。
  • NASH肝硬化患者90天等待名单死亡率显著高于非NASH肝硬化(HR 1.15,p<0.001),1年等待名单死亡率亦显著高于非NASH肝硬化(HR 1.25,p<0.001)。
  • 上述差异在登记时MELD评分较低的患者中更为明显。

关键数值与推荐

  • NASH肝硬化 vs 非NASH肝硬化:90天移植概率HR 0.873(p<0.001),1年移植概率HR 0.867(p<0.001)。
  • MELD评分>30亚组:NASH肝硬化 vs 非NASH肝硬化90天移植概率HR 0.705,1年移植概率HR 0.672(p均<0.001)。
  • NASH肝硬化 vs 非NASH肝硬化:90天等待名单死亡率HR 1.15(p<0.001),1年等待名单死亡率HR 1.25(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) cirrhosis is rapidly growing as an indication for liver transplant(ation) (LT). However, the natural history of NASH cirrhosis among LT waitlist registrants has not been established. The present study aimed to define the natural history of NASH cirrhosis using the Scientific Registry of Transplant Recipients database. METHODS: The study cohort comprised patients registered on the LT waitlist between 1/1/2016 to 12/31/2021. The primary outcomes included probability of LT and waitlist mortality, comparing NASH (n = 8,120) vs. non-NASH (n = 21,409) cirrhosis. RESULTS: Patients with NASH cirrhosis were listed with lower model for end-stage liver disease (MELD) scores despite bearing a greater burden of portal hypertension, especially at lower MELD scores. The overall transplant probability in LT waitlist registrants with NASH [vs. non-NASH] cirrhosis was significantly lower at 90 days (HR 0.873, p <0.001) and 1 year (HR 0.867, p <0.001); this was even more pronounced in patients with MELD scores >30 (HR 0.705 at 90 days and HR 0.672 at 1 year, p <0.001 for both). Serum creatinine was the key contributor to MELD score increases leading to LT among LT waitlist registrants with NASH cirrhosis, while bilirubin was in patients with non-NASH cirrhosis. Finally, waitlist mortality at 90 days (HR 1.15, p <0.001) and 1 year (1.25, p <0.001) was significantly higher in patients with NASH cirrhosis compared to those with non-NASH cirrhosis. These differences were more pronounced in patients with lower MELD scores at the time of LT waitlist registration. CONCLUSIONS: LT waitlist registrants with NASH cirrhosis are less likely to receive a transplant compared to patients with non-NASH cirrhosis. Serum creatinine was the major contributor to MELD score increases leading to LT in patients with NASH cirrhosis. IMPACT AND IMPLICATIONS: This study provides important insights into the distinct natural history of non-alcoholic steatohepatitis (NASH) cirrhosis among liver transplant (LT) waitlist registrants, revealing that patients with NASH cirrhosis face lower odds of transplantation and higher waitlist mortality than those with non-NASH cirrhosis. Our study underscores the significance of serum creatinine as a crucial contributor to model for end-stage liver disease (MELD) score in patients with NASH cirrhosis. These findings have substantial implications, emphasizing the need for ongoing evaluation and refinement of the MELD score to more accurately capture mortality risk in patients with NASH cirrhosis on the LT waitlist. Moreover, the study highlights the importance of further research investigating the impact of the implementation of MELD 3.0 across the US on the natural history of NASH cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lim WH, Ng CH, Tan D, et al. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023. PMID: 37307997. doi:10.1016/j.jhep.2023.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。